Vascular disrupting agents in cancer therapy

Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy

Volumn , Issue , 2008, Pages 809-829

  Tozer, Gillian M ^a   Kanthou, Chryso ^a   Chaplin, David J ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Magdalen Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892130029     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-33177-3_45     Document Type: Chapter

References (54)

1. Ahmed B, Van Eijk LI, Bouma-Ter Steege JC, Van Der Schaft DW, Van Esch AM, Joosten-Achjanie SR, Lambin P, Landuyt W, Griffioen AW (2003) Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int J Cancer 105:20-25
2. Baguley BC (2003) Antivasculart herapy of cancer: DMXAA. Lancet Oncol 4:141-148
3. Baguley BC, Zhuang L, Kestell P (1997) Increased plasma serotonin following treatment with flavone-8-acetic acid, 5, 6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol Res 9:55-60
4. Beerepoot LV, Radema SA, Witteveen EO et al (2006) Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491-1498
5. Blaschuk OW, Rowlands TM (2000) Cadherins as modulators of angiogenesis and the structural integrity of blood vessels. Cancer Metastasis Rev 19:1-5
6. Ching LM, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, Baguley BC (1999) Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59:3304-3307
7. Corada M, Zanetta L, Orsenigo F, Breviario F, Lampugnani MG, Bernasconi S, Liao F, Hicklin DJ, Bohlen P, Dejana E (2002) A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100:905-911
8. Davis PD, Hill SA, Galbraith SM, Chaplin DJ, Naylor MA, Nolan J, Dougherty GJ (2000) ZD6126: a new agent causing selective damage of tumor vasculature. Ninety-first Annual Meeting of the American Association for Cancer Research, vol 41, San Francisco
9. Dong D, Ko B, Baumeister P, Swenson S, Costa F, Markland F, Stiles C, Patterson JB, Bates SE, Lee AS (2005) Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res 65:5785-5791
10. El-Emir E, Boxer GM, Petrie IA, Boden RW, Dearling JL, Begent RH, Pedley RB (2005) Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer 41:799-806
11. Evelhoch JL, Lo Russo PM, He Z, Del Proposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC (2004) Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10:3650-3657
12. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR (2002) Effects of 5, 6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20:3826-3840
13. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21:2831-2842
14. Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC (2000) Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20:229-234
15. Hill SA, Chaplin DJ, Lewis G, Tozer GM (2002) Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int J Cancer 102:70-74
16. Honess DJ, Hylands F, Chaplin DJ, Tozer GM (2002) Comparison of strategies to overcome the hypertensive effect of combretastatin-A-4-phosphate in a rat model. Br J Cancer 86:S118
17. Hori K, Saito S (2003) Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 89:1334-1344
18. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y (1999) Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90:1026-1038
19. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35-52
20. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW, Kestell P (2003) Clinical aspects of a phase I trial of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88:1844-1850
21. Jonker D et al (2005) Proceedings of the American Society of Clinical Oncology (ASCO), annual meeting, abstract 3038
22. Kallinowski F, Schaefer C, Tyler G, Vaupel P (1989) In vivo targets of recombinant human tumour necrosis factora: blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br J Cancer 60:555-560
23. Kanthou C, Tozer GM (2002) The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99:2060-2069
24. Kanthou C, Greco O, Stratford A, Cook I, Knight R, Benzakour O, Tozer G (2004) The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am J Pathol 165:1401-1411
25. Kasibhatla S, Gourdeau H, Meerovitch K, Drewe J, Reddy S, Qiu L, Zhang H, Bergeron F, Bouffard D, Yang Q, Herich J, Lamothe S, Cai SX, Tseng B (2004) Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity. Mol Cancer Ther 3:1365-1374
26. Kirwan IG, Loadman PM, Swaine DJ, Anthoney DA, Pettit GR, Lippert JW 3rd, Shnyder SD, Cooper PA, Bibby MC (2004) Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 10:1446-1453
27. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR (1998) Enhancement of the anti-tumour effects of the antivascular agent 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78:439-445
28. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH (1999) Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 59:6033-6037
29. Li L, Rojiani A, Siemann D (1998) Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 42:899-903
30. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5:436-446
31. Nihei Y, Suzuki M, Okano A, Tsuji T, Akiyama Y, Tsuruo T, Saito S, Hori K, Sato Y (1999) Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 90:1387-1396
32. Otani M, Natsume T, Watanabe J, Kobayashi M, Murakoshi M, Mikami T, Nakayama T (2000) TZT-1027, an antimicrotubule agent attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 91:837-844
33. Pattillo CB, Sari-Sarraf F, Nallamothu R, Moore BM, Wood GC, Kiani MF (2005) Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm Res 22:1117-1120
34. Pedley RB, El-Emir E, Flynn AA, Boxer GM, Dearling J, Raleigh JA, Hill SA, Stuart S, Motha R, Begent RH (2002) Synergy between vascular targeting agents and antibodydirected therapy. Int J Radiat Oncol Biol Phys 54:1524-1531
35. Pettit GR, Lippert JW I I I (2000) Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des 15:203-216
36. Pettit GR, Temple C, Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA, Bansal N (1995) Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10:299-309
37. Platts SH, Falcone JC, Holton WT, Hill MA, Meininger GA (1999) Alteration of microtubule polymerization modulates arteriolar vasomotor tone. Am J Physiol 277:H100-H106
38. Segreti JA, Polakowski JS, Koch KA, Marsh KC, Bauch JL, Rosenberg SH, Sham HL, Cox BF, Reinhart GA (2004) Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 54:273-281
39. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436:568-572
40. Sessa C et al (2003) Proceedings of the 96th annual meeting of the American Association for Cancer Research (AACR), abstract 5827
41. Shaked Y, Ciarrocchi A, Franco M et al (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313 1785-1787
42. Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, Chaplin DJ, Edvardsen K (2004) Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J C ancer 111:604-610
43. Siemann DW, Horsman MR (2002) Enhancement of radiation therapy by vascular targeting agents. Curr Opin Invest Drugs 3:1660-1665
44. Siemann DW, Shi W (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60:1233-1240
45. Siemann DW, Mercer E, Lepler S, Rojiani AM (2002) Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1-6
46. Staton CA, Brown NJ, Rodgers GR, Corke KP, Tazzyman S, Underwood JC, Lewis CE (2004) Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood 103:601-606
47. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427
48. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford M R L, Dennis MF, Chaplin DJ (1999) Combretastatin A-4 phosphate as a tumor vascu lar-targeting agent: early effects in tumors and normal tissues. Cancer Res 59:1626-1634
49. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, Chaplin DJ (2001) Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61:6413-6422
50. Tozer GM, Ameer-Beg SM, Baker J, Barber PR, Hill SA, Hodgkiss RJ, Locke R, Prise VE, Wilson I, Vojnovic B (2005) Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. Adv Drug Deliv Rev 57:135-152
51. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115:2992-3006
52. Wehbe H, Kearney CM, Pinney KG (2005) Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression. Anticancer Res 25:3865-3870
53. Young SL, Chaplin DJ (2004) Combretastatin A4 phosphate: background and current clinical status. Exp Opin Invest Drugs 13:1171-1182
54. Zhao L, Ching LM, Kestell P, Baguley BC (2003) Improvement of the antitumor activity of intraperitoneally and orally administered 5, 6-dimethylxanthenone-4-acetic acid by optimal scheduling. Clin Cancer Res 9:6545-6550